ZEN 3694

Drug Profile

ZEN 3694

Alternative Names: ZEN-3694

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator Zenith Epigenetics Corp
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer
  • Preclinical Breast cancer; Haematological malignancies; Lung cancer

Most Recent Events

  • 19 Jun 2017 Preclinical trials in Breast cancer in Canada (PO) before June 2017 (Zenith Epigenetics pipeline, June 2017)
  • 19 Jun 2017 Preclinical trials in Lung cancer in Canada (PO) before June 2017 (Zenith Epigenetics pipeline, June 2017)
  • 05 Jun 2017 Zenith Epigenetics has patent protection for ZEN-3694, and BET bromodomain inhibitors, in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top